Business
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":" WALTHAM, Mass.--(BUSINESS WIRE)--\nViridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering with gross proceeds of approximately $150.0 million. Viridian is selling a total of 7,142,858 shares of common stock at a public offering price of $21.00 per share. In addition, Viridian has granted the underwriters a 30-day option to purchase an additional 1,071,428 shares of common stock at the public offering price, less underwriting discounts and commissions.\n\n\nAll of the shares to be sold in the underwritten public offering are being offered by Viridian. The offering is expected to close on or about January 22, 2024, subject to customary closing conditions.\n\n\nViridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock, together with its cash, cash equivalents and short-term investments, to further its clinical development programs, as well as for working capital and general corporate purposes.\n\n\nJefferies and Leerink Partners are acting as joint lead book-running managers for the offering.\n\n\nA registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) and became effective on September 9, 2022. A final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering can be made only by means of a prospectus, copies of which may be obtained at the SEC’s website at www.sec.gov, or by request to Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022; telephone: 877-821-7388; email: [email protected]) or Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, ...